6MW3211 + azacitidine

6MW3211 + azacitidine is a combination therapy consisting of **6MW3211**, a bispecific monoclonal antibody targeting both **CD47** and **PD-L1**, and **azacitidine**, a DNA hypomethylating agent. 6MW3211 is designed to block the **CD47/SIRPα** “don’t eat me” signal and **PD-1/PD-L1** immune checkpoint pathway, enhancing macrophage-mediated phagocytosis of tumor cells and promoting T cell activation. This dual blockade aims to bridge innate and adaptive immune responses against cancers, particularly those expressing both CD47 and PD-L1[1][2][4]. Azacitidine, in this combination, provides epigenetic modulation and is standard therapy for myelodysplastic syndromes and acute myeloid leukemia (AML). Mabwell, the developer of 6MW3211, has conducted multiple clinical trials for solid and hematologic tumors, highlighting good tolerability and promising antitumor activity. The combination is under investigation primarily in advanced solid tumors and potentially in hematologic malignancies.